Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Medtronic
McKesson
Baxter
Moodys

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Inotuzumab ozogamicin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Inotuzumab ozogamicin: Patents, clinical trial progress, indications

Inotuzumab ozogamicin is an investigational drug.

There have been 33 clinical trials for Inotuzumab ozogamicin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 26th 2019.

The most common disease conditions in clinical trials are Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, and Leukemia. The leading clinical trial sponsors are Pfizer, UCB Pharma, and M.D. Anderson Cancer Center.

There are fifteen US patents protecting this investigational drug and two hundred and forty-two international patents.

Recent Clinical Trials for Inotuzumab ozogamicin
TitleSponsorPhase
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyNational Cancer Institute (NCI)Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyChildren's Oncology GroupPhase 3
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 1

See all Inotuzumab ozogamicin clinical trials

Clinical Trial Summary for Inotuzumab ozogamicin

Top disease conditions for Inotuzumab ozogamicin
Top clinical trial sponsors for Inotuzumab ozogamicin

See all Inotuzumab ozogamicin clinical trials

US Patents for Inotuzumab ozogamicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Inotuzumab ozogamicin   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Inotuzumab ozogamicin   Start Trial Combination therapy with glutaminase inhibitors and immuno-oncology agents Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
Inotuzumab ozogamicin   Start Trial Stabilizing alkylglycoside compositions and methods thereof Aegis Therapeutics LLC (San Diego, CA)   Start Trial
Inotuzumab ozogamicin   Start Trial Processes for making hydrazides Wyeth LLC (Madison, NJ)   Start Trial
Inotuzumab ozogamicin   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Inotuzumab ozogamicin

Drugname Country Document Number Estimated Expiration Related US Patent
Inotuzumab ozogamicin Australia 2013220749 2032-02-15   Start Trial
Inotuzumab ozogamicin Brazil 112014019627 2032-02-15   Start Trial
Inotuzumab ozogamicin Canada 2862476 2032-02-15   Start Trial
Inotuzumab ozogamicin China 104114705 2032-02-15   Start Trial
Inotuzumab ozogamicin China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
McKesson
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.